Core Viewpoint - Scholar Rock Holding Corp. (NASDAQ:SRRK) is considered a promising multibagger stock, primarily driven by optimism surrounding its lead drug candidate, apitegromab, which has seen significant stock performance fluctuations as the company approaches a potential U.S. market launch in Q3 2025 [1] Group 1: Drug Candidate and Market Potential - Apitegromab is the first muscle-targeted therapy to show clinically meaningful and statistically significant functional improvement in spinal muscular atrophy (SMA), with a global market opportunity estimated to exceed $2 billion [2] - Analyst Amy Li from Jefferies initiated coverage with a Buy rating and a $50 price target, emphasizing the strong commercial opportunity for apitegromab, particularly if FDA approval includes patients aged two and older across SMA types 1-4 [3] - Risk-adjusted peak sales for apitegromab are modeled at $1.8 billion, with a 90% probability of success for patients over two years of age and 50% for those under two [4] Group 2: Pipeline and Future Potential - The company is also developing pipeline candidate SRK-439 for other neuromuscular conditions, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as exploring applications in obesity through external partnerships [5]
Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?